Two indigenous Indian candidate vaccines have got clearance to start early phase human trials this month with both having approximately 1,000 human volunteers each, the Indian Council of Medical Research (ICMR) said on Tuesday. It is unclear if this is ongoing, but given that most clinical trials of humans and vaccines require hundreds if not thousands of test patients, this is still in its infancy.
The vaccine by Cambridge, Massachusetts-based Moderna Inc., generated antibodies similar to those seen in people who have recovered from COVID-19 in a study volunteers who were given either a low or medium dose.
Tarasov added that the first group of volunteers would be discharged on July 15, 2020, followed by the second group on July 20th.
"This research is indeed included in the landscape of candidate vaccines compiled and followed by World Health Organization", the spokesperson said.
"It's a good first step", said Dr William Schaffner, a vaccine expert at Vanderbilt University Medical Center who was not involved in the study. This was more common after the second vaccination, particularly at the highest dose, but none of the side effects were considered serious.
A vaccine candidate has to undergo three different phases before it can be granted approval by a health regulatory authority such as the US' Food and Drug Administration.
However, the researchers said the newly published results cover only the 18 to 55-year age group.
Raids across the south in UK's biggest operation against organised crime
In the United Kingdom alone, more than £50 million in cash has been seized and some 746 suspects arrested as part of " Operation Venetic ".
Moderna said it would enter the final stage of human trials for its COVID-19 vaccine.
Now, the latest development reported from Russian Federation indicates that some organizations have finally made the much-needed headway in developing a vaccine. But more than half the study participants reported flu-like reactions to the shots that aren't uncommon with other vaccines - fatigue, headache, chills, fever and pain at the injection site.
Just a Phase I trial?
The authors of the study, however, noted that they were unable to say how long that immune response lasted, a crucial question when weighing the effectiveness of a vaccine.
The progress made in Russian Federation with regards to finding a potential vaccine is a positive step towards responding to the COVID-19 pandemic.
There was no other information on commercial production of this vaccine, Forbes reported. These moderate side effects were experienced by volunteers who received high doses of the vaccine.
As the world is waiting eagerly for the Coronavirus vaccine, Russia's Sechenov University revealed that the clinical trials of the world's first vaccine against the novel Coronavirus have been completed.